Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046176 · ClinicalTrials.gov registry record · Phase 3
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
A Phase 3 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00046176 is a Phase 3 study that has completed, run by ViiV Healthcare. The registered enrollment target is 240 participants.
The verdict
NCT00046176, a Phase 3 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in ART (antiretroviral)-experienced HIV-1 infected patients.
Interventions
- DRUG lamivudine
- DRUG abacavir/lamivudine
- DRUG abacavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2002-08-26 |
| Est. Completion | 2004-05-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046176
The ClinicalTrials.gov registry entry for NCT00046176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which lamivudine is the first listed.
NCT00046176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046176 about?
NCT00046176 is a clinical study titled "A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients". This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in ART (antiretroviral)-experienced HIV-1 infected patients.
What is the current status of trial NCT00046176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2002-08-26. Estimated completion is 2004-05-17.
What interventions are being tested in trial NCT00046176?
The interventions under investigation include: lamivudine (DRUG), abacavir/lamivudine (DRUG), abacavir (DRUG).
Who is sponsoring clinical trial NCT00046176?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.